Xin Lang Zheng Quan·2025-12-02 03:21Core Viewpoint - Zhaoyan New Drug's stock price has experienced fluctuations, with a year-to-date increase of 67.23%, but recent declines in the short term [1][2] Company Overview - Zhaoyan New Drug Research Center Co., Ltd. was established on February 25, 1998, and listed on August 25, 2017. The company primarily focuses on non-clinical safety evaluation services for drugs and preclinical research services, with a revenue composition of 95.59% from non-clinical research services, 4.34% from clinical services, and 0.07% from experimental model supply [1][2] Financial Performance - For the period from January to September 2025, Zhaoyan New Drug reported operating revenue of 985 million yuan, a year-on-year decrease of 26.23%. However, the net profit attributable to the parent company was 80.71 million yuan, reflecting a significant year-on-year increase of 214.79% [2] - The company has distributed a total of 703 million yuan in dividends since its A-share listing, with 356 million yuan distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, the number of shareholders for Zhaoyan New Drug reached 96,500, an increase of 57.61% compared to the previous period. The average circulating shares per person remained at 0 [2] - Notable changes in institutional holdings include a decrease in shares held by Huabao Zhongzheng Medical ETF and new entries from Guangfa Small Cap Growth Mixed Fund and Guangfa Innovation Upgrade Mixed Fund [3]